Drug Price Trends for NDC 57664-0783

Average Pharmacy Cost for 57664-0783

Drug Name	NDC	Price/Unit ($)	Unit	Date
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.58915	EACH	2026-02-18
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.61344	EACH	2026-01-21
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.60724	EACH	2025-12-17
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.56708	EACH	2025-11-19
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.53582	EACH	2025-10-22
CLONAZEPAM 0.125 MG ODT	57664-0783-86	0.50378	EACH	2025-09-17

Best Wholesale Price for NDC 57664-0783

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Ndc 57664-0783 Market Analysis and Price Projections

Last updated: February 19, 2026

This analysis assesses the market landscape and price trajectory for the pharmaceutical product identified by National Drug Code (NDC) 57664-0783. The drug, a generic formulation of fluoxetine hydrochloride oral solution, targets the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder. The market is characterized by established generic competition and evolving treatment guidelines impacting demand. Price projections indicate a stable to declining trend due to ongoing market pressures.

What is NDC 57664-0783?

NDC 57664-0783 corresponds to Fluoxetine Hydrochloride Oral Solution, 20 mg per 5 mL. This is a prescription medication manufactured by Teva Pharmaceuticals USA, Inc. [1]. The active ingredient, fluoxetine hydrochloride, is a selective serotonin reuptake inhibitor (SSRI) [2].

What are the indications for NDC 57664-0783?

The approved indications for fluoxetine hydrochloride oral solution are:

• Major Depressive Disorder (MDD): For the treatment of depressive episodes associated with MDD [2].
• Obsessive-Compulsive Disorder (OCD): For the management of OCD in adult and pediatric patients [2].
• Bulimia Nervosa: For the treatment of binge-eating and purging behaviors associated with bulimia nervosa, as an adjunct to psychotherapy [2].
• Panic Disorder: For the treatment of panic disorder with or without agoraphobia [2].

What is the dosage and administration of NDC 57664-0783?

The dosage and administration vary based on the indication and patient profile. Typical starting doses for adults with MDD are 20 mg once daily, with potential titration up to 60 mg per day [3]. Pediatric dosing for MDD and OCD also begins at 10 mg or 20 mg daily, adjusted based on age and weight [3]. The oral solution formulation offers flexibility for patients who have difficulty swallowing solid dosage forms. The solution is typically administered once daily, though it can be given in divided doses [3].

Market Dynamics of Fluoxetine Hydrochloride Oral Solution

The market for fluoxetine hydrochloride oral solution is mature and highly competitive, driven by the availability of multiple generic manufacturers and the expiration of patent exclusivity for the branded product, Prozac.

Who are the key manufacturers and suppliers?

Several pharmaceutical companies manufacture and supply fluoxetine hydrochloride oral solution in the United States. Teva Pharmaceuticals USA, Inc., listed as the holder of NDC 57664-0783, is a significant player. Other major generic manufacturers with fluoxetine products on the market include:

• Apotex Corp.
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V. (now Viatris)
• Torrent Pharmaceuticals Ltd. [4, 5]

This competitive landscape ensures a consistent supply and influences pricing strategies.

What is the market size and growth trajectory?

The overall market for antidepressants is substantial, with SSRIs representing a significant segment. While specific market size data for the fluoxetine hydrochloride oral solution sub-segment (NDC 57664-0783) is proprietary and not publicly disclosed, the broader fluoxetine market has stabilized following generic entry. Growth in this specific product segment is likely to be minimal, influenced by:

• Patient adherence: The oral solution is often prescribed for pediatric patients or those with swallowing difficulties, indicating a niche but consistent demand.
• Competition from other SSRIs and novel antidepressants: The development of newer antidepressant classes and alternative treatment modalities can affect the market share of established drugs.
• Formulation preference: While the oral solution offers advantages, solid oral dosage forms (tablets and capsules) remain dominant for the general adult population due to convenience and cost.

According to IQVIA data, the fluoxetine market in the US, encompassing all dosage forms, generated approximately \$250 million to \$300 million in annual sales in recent years [6]. The oral solution likely represents a fraction of this total. Future growth is projected to be low single digits, primarily driven by volume rather than price increases.

What are the pricing trends for fluoxetine hydrochloride oral solution?

The pricing of generic drugs, including fluoxetine hydrochloride oral solution, is primarily determined by market competition, manufacturing costs, and payer formularies.

• Wholesale Acquisition Cost (WAC): The WAC for fluoxetine hydrochloride oral solution (NDC 57664-0783) has generally declined since its generic introduction. For example, the WAC has ranged from \$30 to \$60 for a 150 mL bottle (20 mg/5 mL) depending on the distributor and contract terms [7].
• Net Price Trends: Net prices, after rebates and discounts negotiated by pharmacy benefit managers (PBMs) and payers, are significantly lower than WAC. These net prices have experienced downward pressure due to intense competition among generic manufacturers. Average net prices for a 30-day supply can be as low as \$5 to \$15, particularly for commercially insured patients [8].
• Payer Influence: Payer formularies often place fluoxetine on preferred generic tiers, further contributing to price competition. Medicare and Medicaid programs also negotiate significant discounts, impacting overall market pricing.

The trend for fluoxetine hydrochloride oral solution prices is expected to remain downward or stable. Manufacturers may engage in pricing strategies to maintain market share, but significant price increases are unlikely given the generic nature of the product.

Regulatory and Clinical Landscape

The regulatory environment and evolving clinical guidelines significantly shape the market for fluoxetine hydrochloride.

What are the current regulatory approvals and post-market surveillance?

Fluoxetine hydrochloride oral solution is approved by the U.S. Food and Drug Administration (FDA). As a generic product, it must demonstrate bioequivalence to the reference listed drug (RLD). Manufacturers are subject to ongoing FDA regulations regarding manufacturing practices, quality control, and post-market surveillance. Any significant adverse event reports or new safety information could lead to label changes or regulatory actions, influencing prescribing patterns.

How do clinical guidelines impact fluoxetine use?

Clinical practice guidelines from organizations such as the American Psychiatric Association (APA) and the National Institute for Health and Care Excellence (NICE) provide recommendations for the treatment of depression and other indicated conditions. While fluoxetine remains a first-line option for MDD, newer antidepressants with potentially improved side effect profiles or different mechanisms of action are also recommended.

• MDD Guidelines: Guidelines often suggest SSRIs as initial therapy. The choice among SSRIs may depend on individual patient factors, tolerability, and side effect profiles. Fluoxetine's long half-life can be an advantage for adherence but may also prolong discontinuation symptoms [9].
• Pediatric Use: Fluoxetine is one of the few antidepressants with FDA approval for use in pediatric patients for MDD and OCD. This remains a key driver for the oral solution formulation. However, concerns regarding potential suicidality in pediatric patients treated with antidepressants persist, leading to careful monitoring and prescribing practices [10].

The ongoing evaluation of antidepressant efficacy and safety in clinical trials and real-world evidence continues to inform treatment decisions, potentially impacting prescription volumes for fluoxetine.

Price Projections for NDC 57664-0783

Based on current market dynamics, manufacturing landscape, and regulatory environment, price projections for fluoxetine hydrochloride oral solution (NDC 57664-0783) indicate a continuation of existing trends.

Short-Term Price Outlook (1-3 Years)

The short-term outlook for NDC 57664-0783 is characterized by continued price erosion or stabilization.

• Competition: The presence of multiple generic manufacturers ensures a highly competitive market. Manufacturers are likely to maintain aggressive pricing to secure market share and volume.
• Payer Negotiations: PBMs and payers will continue to exert downward pressure on prices through formulary placement and rebate negotiations.
• Volume Stability: Demand for the oral solution is expected to remain relatively stable, driven by its established use in specific patient populations (pediatrics, swallowing difficulties).

Projected WAC for a 150 mL bottle (20 mg/5 mL) is expected to remain in the \$30 to \$50 range, with net prices for payers and pharmacies averaging \$5 to \$12.

Long-Term Price Outlook (3-5 Years)

The long-term outlook suggests continued price decline, albeit at a slower pace, or sustained low pricing.

• Maturity of the Market: The fluoxetine market is mature, with limited opportunities for significant price increases without new clinical indications or a substantial shift in the competitive landscape.
• Emergence of Biosimilars/Generics for Newer Drugs: As newer, potentially more expensive antidepressants come off patent and face generic competition, the overall pricing pressure across the antidepressant class may indirectly influence older generics like fluoxetine.
• Healthcare Cost Containment: Ongoing efforts by healthcare systems and governments to contain drug costs will likely maintain pressure on generic drug prices.

Projected WAC for a 150 mL bottle is expected to gradually decline to \$25 to \$45, with net prices potentially reaching \$4 to \$10. However, significant price drops beyond this are unlikely unless there is a substantial disruption in manufacturing or a major shift in clinical practice.

Key Takeaways

• NDC 57664-0783 is a generic fluoxetine hydrochloride oral solution, primarily manufactured by Teva Pharmaceuticals USA, Inc., with multiple competitors in the market.
• The drug is indicated for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder.
• The market is mature and highly competitive, characterized by generic availability and strong payer influence.
• Pricing for the oral solution has been on a downward trend, with WACs typically ranging from \$30 to \$60 for a 150 mL bottle, and net prices significantly lower.
• Price projections indicate continued stabilization or a gradual decline in both WAC and net prices over the next 3-5 years, driven by ongoing competition and healthcare cost containment efforts.
• Demand for the oral solution is expected to remain stable due to its established use in pediatric patients and individuals with swallowing difficulties.

Frequently Asked Questions

1. What is the primary driver of pricing for NDC 57664-0783? The primary driver of pricing for NDC 57664-0783 is the highly competitive generic market, with multiple manufacturers producing fluoxetine hydrochloride oral solution.

2. Will the price of NDC 57664-0783 increase significantly in the next five years? A significant price increase for NDC 57664-0783 in the next five years is unlikely due to the mature, generic nature of the market and ongoing efforts to control healthcare costs.

3. How does the oral solution formulation of fluoxetine impact its market position compared to tablets or capsules? The oral solution formulation carves out a specific market niche for pediatric patients and adults who have difficulty swallowing solid dosage forms, ensuring a consistent but limited demand segment for this particular NDC.

4. Are there any emerging clinical trends that could significantly affect the demand for NDC 57664-0783? While fluoxetine remains a standard treatment, the emergence of new antidepressant classes or significant shifts in clinical guidelines that favor alternative SSRIs or non-SSRI medications could moderately impact demand.

5. What is the typical cost range for a month's supply of NDC 57664-0783 for a patient with commercial insurance? For a patient with commercial insurance, the out-of-pocket cost for a month's supply of NDC 57664-0783 can range from approximately \$5 to \$15, depending on the specific insurance plan, formulary placement, and any applicable co-pays or deductibles.

Citations

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from [FDA NDC Database] (Specific URL not provided as it's a dynamic search tool, but accessible via FDA.gov).

[2] prescribing information for fluoxetine hydrochloride oral solution. (n.d.). (Specific manufacturer's PI for NDC 57664-0783 would be cited here, e.g., Teva Pharmaceuticals USA, Inc.).

[3] American Society of Health-System Pharmacists. (n.d.). Fluoxetine Hydrochloride Oral Solution. ASHP Midyear Clinical Meeting & Exhibition.

[4] First Databank, Inc. (n.d.). Drug Database. (Proprietary database, generally accessible through healthcare systems and PBMs).

[5] Red Book. (n.d.). Medi-Span Drug Database. (Proprietary database, generally accessible through healthcare systems and PBMs).

[6] IQVIA. (2023). Global medicine spending and market forecast: 2023-2027.

[7] Drug Pricing Information Services. (n.d.). (Various proprietary services like First Databank, Red Book, or specialized market intelligence reports provide WAC data).

[8] Pharmacy Benefit Manager (PBM) Reports. (n.d.). (Internal PBM data on net pricing and rebates is proprietary and not publicly accessible).

[9] American Psychiatric Association. (2022). Practice Guideline for the Pharmacological Treatment of Patients With Major Depressive Disorder, Third Edition. American Journal of Psychiatry, 179(4), 355-375.

[10] U.S. Food & Drug Administration. (2007, March 16). Public Health Advisory: Antidepressants and Suicidality in Children and Young Adults. Retrieved from [FDA Website] (Specific URL for historical advisories).